The buzz over Pfizer's biopharma ambitions continues with analyst George Grofik speculating about the possibilities of a Biogen Idec acquisition versus, say, Amgen or Wyeth [1]. Biogen Idec's starting price is around $23 billion [2], while Amgen could fetch $62 billion, give or take a few billion. Grofik is looking for a few bite-sized acquisitions followed by a mid-sized buyout for Pfizer. But that doesn't leave the pharma giant looking any better to the analyst. Grofik still has the company stock on "hold."
- read the report [3] from the Wall Street Journal (sub. req.)
ALSO: It's official: Pfizer is killing off Exubera. Report [4]
Related Articles:
Who should Pfizer buy? Report [5]
Pfizer hires new R&D chief, launches biotech center. Report [6]
Pfizer's future rests with biotech. Report [7]
Biogen Idec in play after Icahn makes his move. Report [2]
Read more on: Pfizer [8]Â |Â Biogen Idec [9] | Amgen [10]Â | Wyeth [11]
Links:
[1] http://www.fiercepharma.com/story/pfizer-wyeth-merger-bad-idea/2007-08-27
[2] http://www.fiercebiotech.com/story/biogen-idec-play-after-icahn-makes-his-move/2007-10-15
[3] http://blogs.wsj.com/health/2007/10/17/pfizer-focusing-on-bite-size-biotech/
[4] http://www.fiercepharma.com/story/pfizer-kills-exubera-hunts-deals/2007-10-18
[5] http://www.fiercepharma.com/story/who-should-pfizer-buy/2007-10-16
[6] http://www.fiercebiotech.com/story/pfizer-hires-new-r-d-chief-launches-biotech-center/2007-10-04
[7] http://www.fiercebiotech.com/story/pfizers-future-rests-biotech/2007-09-13
[8] http://www.fiercebiotech.com/tags/pfizer
[9] http://www.fiercebiotech.com/tags/biogen-idec
[10] http://www.fiercebiotech.com/tags/amgen
[11] http://www.fiercepharma.com/tags/wyeth